{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:35Z","timestamp":1780470215071,"version":"3.54.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Laboratory Medicine and Pathology of Mayo Clinic Rochester","award":["010DF2016"],"award-info":[{"award-number":["010DF2016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p\/>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Paragangliomas have unique features in the mediastinum, in part due to their location. Because of their paucity, they have not been thoroughly investigated. We studied the clinical, pathological, immunohistochemical and molecular features of mediastinal paragangliomas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Immunohistochemistry, next-generation sequencing mutation panel and the Oncoscan assay were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Twenty-four patients with mediastinal paraganglioma (7 men, 29.2%) had a median age of 45.5\u2009years (19.8\u201372.2). Twenty-one (87.5%) paragangliomas were completely resected. Six (of 24, 25.0%) tumours were considered metastatic. Mitotic activity occurred in 11 (of 24, 45.8%) paragangliomas. Programmed death-ligand 1 (PD-L1) (n\u2009=\u200923) was expressed in 6 (26%) patients in 10% (n\u2009=\u20092) and 1% (n\u2009=\u20094) of tumour cells, respectively. SDHB expression was lost in 19 (of 22, 86.4%) cases. ATRX expression was lost in 11 (of 23, 47.8%) cases. Next-generation sequencing revealed a single pathogenic mutation in 10 (of 19) specimens including SDHB (n\u2009=\u20094), SDHD (n\u2009=\u20096), SDHC (n\u2009=\u20091), ATRX (n\u2009=\u20091), and \u22652 mutations in 2 cases [SDHC and TERT (n\u2009=\u20091); SDHB, ATRX and TP53 (n\u2009=\u20091)]. Germline mutation analysis revealed the same succinate dehydrogenase mutation (or lack thereof) as identified in the paraganglioma in 11 (of 12) cases. During a median follow-up (n\u2009=\u200921) of 4.8\u2009years (0.8\u201314.9), 3 patients developed metastases; 4 patients died, at least 1 of disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Mediastinal paragangliomas can be associated with morbidity and mortality. Many mediastinal paragangliomas have been reported to be associated with syndromes such as multiple endocrine neoplasia, von Hippel-Lindau or succinate dehydrogenase syndrome with mutation profiles dominated by alterations in genes associated with these syndromes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejcts\/ezz115","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T16:12:31Z","timestamp":1553184751000},"page":"867-875","source":"Crossref","is-referenced-by-count":11,"title":["Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas\u2020"],"prefix":"10.1093","volume":"56","author":[{"given":"Ying-Han R","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Torres-Mora","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R","family":"Kipp","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Sukov","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse S","family":"Voss","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G","family":"Barr Fritcher","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartzell V","family":"Schaff","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D","family":"Cassivi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja C","family":"Roden","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"2019101705190979100_ezz115-B1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"key":"2019101705190979100_ezz115-B2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2019101705190979100_ezz115-B3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2017.07.014","article-title":"Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature","volume":"249","author":"Zhang","year":"2017","journal-title":"Int J Cardiol"},{"key":"2019101705190979100_ezz115-B4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.amjcard.2016.03.019","article-title":"Clinical features and outcome of pheochromocytoma-induced takotsubo syndrome: analysis of 80 published cases","volume":"117","author":"Y-Hassan","year":"2016","journal-title":"Am J Cardiol"},{"key":"2019101705190979100_ezz115-B5","first-page":"Doc03","article-title":"Paragangliomas and paraganglioma syndromes","volume":"10","author":"Boedeker","year":"2011","journal-title":"GMS Curr Top Otorhinolaryngol Head Neck Surg"},{"key":"2019101705190979100_ezz115-B6","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/ERC-11-0170","article-title":"Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas","volume":"18","author":"Welander","year":"2011","journal-title":"Endocrin Relat Cancer"},{"key":"2019101705190979100_ezz115-B7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.athoracsur.2008.04.105","article-title":"Mediastinal paragangliomas: the mayo clinic experience","volume":"86","author":"Brown","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"2019101705190979100_ezz115-B8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/his.13402","article-title":"Pathology and genetics of phaeochromocytoma and paraganglioma","volume":"72","author":"Turchini","year":"2018","journal-title":"Histopathology"},{"key":"2019101705190979100_ezz115-B9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00401-017-1727-5","article-title":"Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p\/19q-codeleted in a patient with CCDC26 polymorphism","volume":"134","author":"Vaubel","year":"2017","journal-title":"Acta Neuropathol"},{"key":"2019101705190979100_ezz115-B10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jcin.2017.02.035","article-title":"Percutaneous coronary intervention for treatment of paraganglioma with coronary vascularization","volume":"10","author":"Gonzalez-Ferreiro","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2019101705190979100_ezz115-B11","doi-asserted-by":"crossref","first-page":"e0168413","DOI":"10.1371\/journal.pone.0168413","article-title":"Disentangling of malignancy from benign pheochromocytomas\/paragangliomas","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"2019101705190979100_ezz115-B12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/ERC-08-0214","article-title":"Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior","volume":"16","author":"Ghayee","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"2019101705190979100_ezz115-B13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2015.03.020","article-title":"Succinate dehydrogenase gene mutations in cardiac paragangliomas","volume":"115","author":"Martucci","year":"2015","journal-title":"Am J Cardiol"},{"key":"2019101705190979100_ezz115-B14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/eurheartj\/ehx007","article-title":"Succinate dehydrogenase gene mutation with cardiac paraganglioma: multimodality imaging and pathological correlation","volume":"38","author":"Romano","year":"2017","journal-title":"Eur Heart J"},{"key":"2019101705190979100_ezz115-B15","doi-asserted-by":"crossref","first-page":"e1358332","DOI":"10.1080\/2162402X.2017.1358332","article-title":"Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior","volume":"6","author":"Pinato","year":"2017","journal-title":"Oncoimmunology"},{"key":"2019101705190979100_ezz115-B16","article-title":"The phosphatidylinositol 3-kinase\/Akt signaling pathway in neuroendocrine tumors","volume":"3","author":"Somnay","year":"2012","journal-title":"Glob J Biochem"},{"key":"2019101705190979100_ezz115-B17","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s00268-009-0175-3","article-title":"Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells","volume":"33","author":"Adler","year":"2009","journal-title":"World J Surg"},{"key":"2019101705190979100_ezz115-B18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fendo.2015.00126","article-title":"Pheochromocytomas and paragangliomas: clinical and genetic approaches","volume":"6","author":"Costa","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2019101705190979100_ezz115-B19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1210\/jc.2010-1588","article-title":"Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location","volume":"96","author":"Eisenhofer","year":"2011","journal-title":"J Clin Endocrin Metabol"},{"key":"2019101705190979100_ezz115-B20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis","volume":"10","author":"van Nederveen","year":"2009","journal-title":"Lancet Oncol"},{"key":"2019101705190979100_ezz115-B21","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/PAS.0000000000000534","article-title":"Urinary bladder paragangliomas: how immunohistochemistry can assist to identify patients with SDHB germline and somatic mutations","volume":"39","author":"Giubellino","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"2019101705190979100_ezz115-B22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/gim.2014.162","article-title":"Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations","volume":"17","author":"Evenepoel","year":"2015","journal-title":"Genet Med"},{"key":"2019101705190979100_ezz115-B23","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene","volume":"107","author":"Cascon","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2019101705190979100_ezz115-B24","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","article-title":"Germline FH mutations presenting with pheochromocytoma","volume":"99","author":"Clark","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2019101705190979100_ezz115-B25","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"key":"2019101705190979100_ezz115-B26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1530\/ERC-13-0429","article-title":"Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia","volume":"21","author":"Papathomas","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2019101705190979100_ezz115-B27","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1155\/2015\/138573","article-title":"Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis","volume":"2015","author":"Luchetti","year":"2015","journal-title":"Int J Endocrinol"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ejcts\/article-pdf\/56\/5\/867\/30159347\/ezz115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ejcts\/article-pdf\/56\/5\/867\/30159347\/ezz115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T05:19:29Z","timestamp":1571289569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/56\/5\/867\/5474974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,4,16]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezz115","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"value":"1010-7940","type":"print"},{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,4,16]]}}}